Claim · model-written summary
The pendimethalin weed dry-weight reduction fell by 2530% at 60 DAS.
- Taxon
- cluster bean
Cyamopsis tetragonolobat0 - Interactor
- weede0weed
- Outcome
- weed dry weighte0
- Direction
- lowerede0
- Value
- 2530%e0
- Qualifier
- at 60 DASe0
Not reportedMaterialGeneCompoundOrgan / stageSecond interactorSecond interactor roleTreatmentComparatorSetting
Organisms pictured · Representative pictures of the matched species, not figures from the paper.
Verbatim
e0“however at 60 DAS percent reduction of weed dry weight was lowered by 2530% under both the soil texture”
t0“cluster bean”
Title
MEENAKSHI SANGWAN; SAMUNDER SINGH; SATYAVAN Indian Journal of Agronomy 2001. doi:10.59797/ija.v61i4.4406
Other claims from this paper (13)
- Intervention effect Pendimethalin reduced weed dry weight by 8590% through 30 DAS.
- Intervention effect Sequential imazethapyr then propaquizafop reduced weed dry weight by 95% at Kheri Batter.
- Intervention effect Sequential imazethapyr then propaquizafop reduced weed dry weight by 91% at Hisar.
- Intervention effect The imazethapyr–imazamox then propaquizafop sequence matched the maximum weed reduction treatment.
- Observation Imazethapyr plus imazamox had lower efficacy in sandy loam than loamy sand.
- Intervention effect The imazethapyr then propaquizafop sequence had highest seed yield at Kheri Batter.
- Intervention effect The imazethapyr then propaquizafop sequence had highest net returns at Kheri Batter.
- Intervention effect The imazethapyr plus imazamox then propaquizafop sequence had highest seed yield at Kheri Batter.
- Intervention effect The imazethapyr plus imazamox then propaquizafop sequence had highest net returns at Kheri Batter.
- Intervention effect The imazethapyr then propaquizafop sequence had highest seed yield at Hisar.
- Intervention effect The imazethapyr then propaquizafop sequence had highest net returns at Hisar.
- Intervention effect At Hisar, the imazethapyr plus imazamox sequence had lower yield.
- Intervention effect At Hisar, the imazethapyr plus imazamox sequence had lower net returns.